Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

Key Terms

parkinson’s disease psychosis medical

A complication of Parkinson’s disease in which people experience hallucinations, false beliefs, or confused thinking that arise from the illness itself or as a side effect of its treatments. It matters to investors because it creates a distinct medical need and market for safer therapies, influences clinical trial design and regulatory review, and can affect healthcare costs and drug sales; think of it as a car’s warning lights misfiring, prompting demand for better, more reliable fixes.

rett syndrome medical

A rare genetic disorder that disrupts normal brain development in young children, most commonly girls, leading to slowed growth, loss of purposeful hand use, repetitive hand movements, motor problems, speech loss, and cognitive and breathing irregularities. Investors watch it because its severity and few treatment options create clear medical need and potential markets for therapies; think of it as a broken traffic signal in the brain that, if fixed, could restore many downstream functions.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time.

The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived for approximately 90 days. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260715126610/en/

Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com

Source: Acadia Pharmaceuticals Inc.